Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-09-17 21:30:33 ET · period of report 2026-09-15 · accession 0001943192-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-17 21:30 | 2026-09-15 | TVTX | Cline Christopher R. | CFO | M - OptEx | $17.44 | +20.0K | 138.0K | +17% | +$348.8K |
| DMT | 2026-09-17 21:30 | 2026-09-15 | TVTX | Cline Christopher R. | CFO | S - Sale+OE | $62.34 | -50.5K | 87.5K | -37% | -$3.15M |
| DT | 2026-09-17 21:30 | 2026-09-15 | TVTX | Cline Christopher R. | CFO | M - OptEx | $0.00 | -20.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | M | A | 20,000 | $17.44 | 138,016 | D | — | — | |
| 2 | Common | Common Stock | 2026-09-15 | S | D | 27,473 | $62.00 | 110,543 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. (F2) The weighted average sale price for the transaction reported was $61.9969, and the range of prices were between $61.38 and $62.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 3 | Common | Common Stock | 2026-09-15 | S | D | 20,735 | $62.61 | 89,808 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. (F3) The weighted average sale price for the transaction reported was $62.6079, and the range of prices were between $62.38 and $63.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 4 | Common | Common Stock | 2026-09-15 | S | D | 1,900 | $63.69 | 87,908 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. (F4) The weighted average sale price for the transaction reported was $63.6865, and the range of prices were between $63.59 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 5 | Common | Common Stock | 2026-09-15 | S | D | 400 | $65.31 | 87,508 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. |
| 6 | Derivative | Employee stock option (right to buy) | 2026-09-15 | M | D | 20,000 | $0.00 | 0 | D | $17.44 · — to 2027-05-17 | 20,000 Common Stock | (F5) The stock option is fully vested and exercisable. |